A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)

Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The...

Full description

Saved in:
Bibliographic Details
Published inCephalalgia Vol. 38; no. 6; pp. 1038 - 1048
Main Authors Starling, Amaal J, Tepper, Stewart J, Marmura, Michael J, Shamim, Ejaz A, Robbins, Matthew S, Hindiyeh, Nada, Charles, Andrew C, Goadsby, Peter J, Lipton, Richard B, Silberstein, Stephen D, Gelfand, Amy A, Chiacchierini, Richard P, Dodick, David W
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.05.2018
Subjects
Adolescent
Adult
Aged
Female
Humans
Male
Middle Aged
Migraine Disorders - prevention & control
Original
Prospective Studies
Transcranial Magnetic Stimulation - methods
Treatment Outcome
Young Adult
transcranial magnetic stimulation
preventive treatment
single-pulse
Migraine
Online AccessGet full text

Cover

Abstract Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The e Neura S pringTMS P ost-Market O bservational U .S. S tudy of Migrain e (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a −2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (−0.63 days) (p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher (p < 0.0001) than the performance goal (20%). There was a reduction of −2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, −3.1 (6.4) (p < 0.0001), and total headache days of any intensity −3.16 days (5.21) compared to the performance goal (−0.63 days) (p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381
AbstractList Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a -2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (-0.63 days) ( p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher ( p < 0.0001) than the performance goal (20%). There was a reduction of -2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, -3.1 (6.4) ( p < 0.0001), and total headache days of any intensity -3.16 days (5.21) compared to the performance goal (-0.63 days) ( p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381.
Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The e Neura S pringTMS P ost-Market O bservational U .S. S tudy of Migrain e (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a −2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (−0.63 days) (p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher (p < 0.0001) than the performance goal (20%). There was a reduction of −2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, −3.1 (6.4) (p < 0.0001), and total headache days of any intensity −3.16 days (5.21) compared to the performance goal (−0.63 days) (p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381
Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a -2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (-0.63 days) ( p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher ( p < 0.0001) than the performance goal (20%). There was a reduction of -2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, -3.1 (6.4) ( p < 0.0001), and total headache days of any intensity -3.16 days (5.21) compared to the performance goal (-0.63 days) ( p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381.Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a -2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (-0.63 days) ( p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher ( p < 0.0001) than the performance goal (20%). There was a reduction of -2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, -3.1 (6.4) ( p < 0.0001), and total headache days of any intensity -3.16 days (5.21) compared to the performance goal (-0.63 days) ( p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381.
Author Chiacchierini, Richard P
Starling, Amaal J
Goadsby, Peter J
Silberstein, Stephen D
Shamim, Ejaz A
Tepper, Stewart J
Robbins, Matthew S
Lipton, Richard B
Gelfand, Amy A
Marmura, Michael J
Charles, Andrew C
Hindiyeh, Nada
Dodick, David W
AuthorAffiliation 10 R. P. Chiacchierini Consulting, Gaithersburg, MD, USA
1 Mayo Clinic, Phoenix, AZ, USA
7 UCLA Headache Research and Treatment Program, Los Angeles, CA, USA
4 Mid-Atlantic Permanente Research Institute (Kaiser Permanente Mid-Atlantic States), Rockville, MD, USA
5 Montefiore Headache Center, 171460 Albert Einstein College of Medicine , Bronx, NY, USA
8 NIHR-Wellcome Trust King's Clinical Research Facility, Kings College London, UK
3 Jefferson Headache Center, Philadelphia, PA, USA
6 Stanford Headache Program, Stanford, CA, USA
2 The Geisel School of Medicine at Dartmouth, Hanover, NH, USA
9 UCSF, San Francisco, CA, USA
AuthorAffiliation_xml – name: 5 Montefiore Headache Center, 171460 Albert Einstein College of Medicine , Bronx, NY, USA
– name: 10 R. P. Chiacchierini Consulting, Gaithersburg, MD, USA
– name: 7 UCLA Headache Research and Treatment Program, Los Angeles, CA, USA
– name: 8 NIHR-Wellcome Trust King's Clinical Research Facility, Kings College London, UK
– name: 1 Mayo Clinic, Phoenix, AZ, USA
– name: 2 The Geisel School of Medicine at Dartmouth, Hanover, NH, USA
– name: 6 Stanford Headache Program, Stanford, CA, USA
– name: 9 UCSF, San Francisco, CA, USA
– name: 4 Mid-Atlantic Permanente Research Institute (Kaiser Permanente Mid-Atlantic States), Rockville, MD, USA
– name: 3 Jefferson Headache Center, Philadelphia, PA, USA
Author_xml – sequence: 1
  givenname: Amaal J
  surname: Starling
  fullname: Starling, Amaal J
  email: starling.amaal@mayo.edu
– sequence: 2
  givenname: Stewart J
  surname: Tepper
  fullname: Tepper, Stewart J
– sequence: 3
  givenname: Michael J
  surname: Marmura
  fullname: Marmura, Michael J
– sequence: 4
  givenname: Ejaz A
  surname: Shamim
  fullname: Shamim, Ejaz A
– sequence: 5
  givenname: Matthew S
  surname: Robbins
  fullname: Robbins, Matthew S
– sequence: 6
  givenname: Nada
  surname: Hindiyeh
  fullname: Hindiyeh, Nada
– sequence: 7
  givenname: Andrew C
  surname: Charles
  fullname: Charles, Andrew C
– sequence: 8
  givenname: Peter J
  orcidid: 0000-0003-3260-5904
  surname: Goadsby
  fullname: Goadsby, Peter J
– sequence: 9
  givenname: Richard B
  surname: Lipton
  fullname: Lipton, Richard B
– sequence: 10
  givenname: Stephen D
  surname: Silberstein
  fullname: Silberstein, Stephen D
– sequence: 11
  givenname: Amy A
  surname: Gelfand
  fullname: Gelfand, Amy A
– sequence: 12
  givenname: Richard P
  surname: Chiacchierini
  fullname: Chiacchierini, Richard P
– sequence: 13
  givenname: David W
  surname: Dodick
  fullname: Dodick, David W
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29504483$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1rFDEYDlKx2-rdk-RYYUeTTDKTuQilrB9QqbDtOWQyb9aUzGRMZlb67810W9GCnhJ4vnif5wQdDWEAhF5T8o7Sun5PyrKkhHEq64oJJp6hFeWVLFgj2RFaLXCx4MfoJKVbQoioSPUCHbNGEM5luUI_z3E_-8kZGCaIazzGkEYwk9vDGic37DxgHfs1DiMM2OsWfP63CeJeTy4M2uM0zd0dDhan669bbEPEvdtF7QbIbrDPxpmHzzbbb1c32w3eLvS3L9Fzq32CVw_vKbr5uLm--FxcXn36cnF-WRhByFQ0zNadLmtrGim5bLnmVtjKdlZS21JrLGk1My1j0HChTUs73WhRdlpUQuiyPEUfDr7j3PbQLWdG7dUYXa_jnQraqb-RwX1Xu7BXouGc1DIbnD0YxPBjhjSp3iUD3usBwpwUI5RIXrJ76ps_s36HPLadCdWBYHLLKYJVxk33NeZo5xUlaplVPZ01C8kT4aP3fyTFQZL0DtRtmGPeKv2b_wusGLIf
CitedBy_id crossref_primary_10_1111_dme_15519
crossref_primary_10_1007_s11916_018_0716_2
crossref_primary_10_1016_j_brs_2021_10_383
crossref_primary_10_1080_14737175_2019_1585243
crossref_primary_10_47102_annals_acadmed_sg_2019255
crossref_primary_10_1016_j_clinph_2021_06_015
crossref_primary_10_1007_s11916_022_01024_y
crossref_primary_10_1212_CON_0000000000001237
crossref_primary_10_1007_s11916_020_00914_3
crossref_primary_10_5812_aapm_110515
crossref_primary_10_1007_s00702_019_02092_y
crossref_primary_10_1108_MIJ_10_2019_0004
crossref_primary_10_1016_j_nrleng_2020_04_017
crossref_primary_10_1080_14728214_2018_1552939
crossref_primary_10_1007_s11910_020_1021_0
crossref_primary_10_17340_jkna_2020_2_3
crossref_primary_10_1097_WNO_0000000000001053
crossref_primary_10_1111_head_13479
crossref_primary_10_1111_ner_13319
crossref_primary_10_1007_s13311_020_00879_6
crossref_primary_10_3390_brainsci12060761
crossref_primary_10_1007_s00415_023_11880_2
crossref_primary_10_1055_s_0042_1758781
crossref_primary_10_1212_WNL_0000000000207677
crossref_primary_10_1007_s00415_023_11706_1
crossref_primary_10_1212_CON_0000000000000957
crossref_primary_10_31636_pmjua_v3i4_2
crossref_primary_10_1093_brain_awz405
crossref_primary_10_1007_s11916_025_01366_3
crossref_primary_10_31083_j_jin2104110
crossref_primary_10_1111_ene_14747
crossref_primary_10_1186_s10194_022_01428_6
crossref_primary_10_1016_j_nrl_2020_04_022
crossref_primary_10_1080_14737175_2020_1797493
crossref_primary_10_1016_j_nicl_2023_103543
crossref_primary_10_5604_01_3001_0054_4389
crossref_primary_10_1016_S0140_6736_18_30478_1
crossref_primary_10_1212_CPJ_0000000000000654
crossref_primary_10_17116_jnevro201911910179
crossref_primary_10_1038_s41582_021_00516_6
crossref_primary_10_1002_ana_25387
crossref_primary_10_1007_s00482_019_0388_9
crossref_primary_10_1136_jnnp_2018_320113
crossref_primary_10_7759_cureus_34553
crossref_primary_10_36290_neu_2018_116
crossref_primary_10_1111_head_13414
crossref_primary_10_1111_head_13656
crossref_primary_10_1007_s11916_021_00988_7
crossref_primary_10_1097_JXX_0000000000000397
crossref_primary_10_3390_ijerph18010246
crossref_primary_10_1111_ane_13034
crossref_primary_10_1097_WCO_0000000000000557
crossref_primary_10_4103_0028_3886_315998
crossref_primary_10_1111_ner_13094
crossref_primary_10_3390_biomedicines12020288
crossref_primary_10_1016_j_neurol_2021_07_009
crossref_primary_10_1111_ner_13127
crossref_primary_10_5694_mja2_50435
crossref_primary_10_1186_s10194_019_1066_0
crossref_primary_10_1097_WNO_0000000000000837
crossref_primary_10_3892_mmr_2022_12625
crossref_primary_10_5604_01_3001_0014_4591
crossref_primary_10_1097_WCO_0000000000000820
crossref_primary_10_1016_j_mayocp_2018_09_006
crossref_primary_10_1371_journal_pone_0292733
crossref_primary_10_17925_USN_2022_18_2_103
crossref_primary_10_36290_neu_2019_013
crossref_primary_10_1038_s41572_022_00415_0
crossref_primary_10_1055_s_0042_1757926
crossref_primary_10_4103_abr_abr_142_23
crossref_primary_10_2217_bem_2019_0024
crossref_primary_10_2169_internalmedicine_4846_24
crossref_primary_10_1038_s41598_020_62701_9
crossref_primary_10_1016_j_brs_2020_05_010
crossref_primary_10_3389_fphar_2019_00032
crossref_primary_10_3389_fpsyt_2022_875227
crossref_primary_10_1007_s11916_024_01344_1
crossref_primary_10_1016_j_ncl_2019_07_004
crossref_primary_10_34883_PI_2020_10_4_043
crossref_primary_10_1016_j_ncl_2019_07_006
crossref_primary_10_3389_fneur_2022_919623
crossref_primary_10_1109_LMAG_2024_3371370
crossref_primary_10_1111_nmo_14899
crossref_primary_10_3390_ijms23063018
crossref_primary_10_1111_head_13586
crossref_primary_10_1007_s11916_022_01025_x
crossref_primary_10_1007_s11910_022_01224_4
crossref_primary_10_1111_head_14153
crossref_primary_10_3390_jcm10153302
crossref_primary_10_1007_s11916_023_01162_x
crossref_primary_10_1177_0333102420941864
crossref_primary_10_1177_0333102419876920
crossref_primary_10_1111_head_13456
crossref_primary_10_17816_ACEN_1152
crossref_primary_10_3389_fneur_2022_793253
crossref_primary_10_1177_2515816319889971
crossref_primary_10_3389_fneur_2019_00364
crossref_primary_10_1055_a_1933_4366
Cites_doi 10.1093/biomet/75.4.800
10.1002/9780470316696
10.1111/j.1526-4610.2010.01697.x
10.1016/S1474-4422(03)00321-1
10.1016/S1388-2457(01)00693-9
10.1186/s10194-015-0543-3
10.1002/ana.20778
10.1212/WNL.0b013e3182825055
10.1111/j.1526-4610.2007.00757.x
10.1177/0333102416678382
10.1136/jnnp.2009.192492
10.1177/0333102414547138
10.1016/j.jns.2004.08.008
10.1016/S1474-4422(10)70054-5
10.1016/S1388-2457(02)00109-8
10.1111/head.12353
10.1177/0333102413515340
10.1212/WNL.0b013e3182535d0c
10.1016/S1388-2457(99)00323-5
10.1111/j.1526-4610.2006.00565.x
10.1111/j.1468-2982.2009.02021.x
10.1016/S1388-2457(01)00585-5
10.1016/j.neuroscience.2009.03.019
10.1038/nn.2475
10.1111/head.12774
10.1001/archneur.61.4.490
10.1016/j.ejpain.2007.03.002
10.1111/head.13002
10.1186/s10194-015-0535-3
10.1007/s11916-006-0049-4
10.1016/S0140-6736(16)31678-6
10.1177/096228029300200202
10.1111/j.1526-4610.2012.02265.x
10.1177/0333102413485658
10.1007/s10194-011-0348-y
10.1002/ana.21994
10.1007/s00415-013-7072-2
10.1111/j.1468-2982.2009.01911.x
10.1001/jama.291.8.965
10.1046/j.1526-4610.2002.0420s1003.x
10.1212/01.wnl.0000252808.97649.21
10.1093/brain/aww118
ContentType Journal Article
Copyright International Headache Society 2018
International Headache Society 2018 2018 International Headache Society
Copyright_xml – notice: International Headache Society 2018
– notice: International Headache Society 2018 2018 International Headache Society
DBID AFRWT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1177/0333102418762525
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2982
EndPage 1048
ExternalDocumentID PMC5944078
29504483
10_1177_0333102418762525
10.1177_0333102418762525
Genre Multicenter Study
Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GrantInformation_xml – fundername: eNeura Inc.
– fundername: ;
GroupedDBID ---
-TM
.2F
.2G
.3N
.GJ
.Y3
01A
0R~
1OC
29B
31S
31T
31Y
31~
36B
4.4
53G
54M
5GY
5RE
5VS
6PF
8-1
AABMB
AABOD
AACKU
AADUE
AAGGD
AAHHS
AAJIQ
AAJOX
AAJPV
AANSI
AAPEO
AAQDB
AAQXH
AARDL
AARIX
AASGM
AAWTL
AAXOT
AAYTG
AAZBJ
ABAWC
ABAWP
ABCCA
ABCQN
ABDBF
ABDWY
ABEIX
ABFWQ
ABHKI
ABIVO
ABJIS
ABJNI
ABKRH
ABNCE
ABPGX
ABQKF
ABQXT
ABRHV
ABVFX
ABVVC
ABYTW
ACARO
ACCFJ
ACDSZ
ACDXX
ACFMA
ACFYK
ACGBL
ACGFS
ACLHI
ACNXM
ACOFE
ACROE
ACRPL
ACUHS
ACXQS
ADBBV
ADEBD
ADEIA
ADMPF
ADNBR
ADNMO
ADOGD
ADSTG
ADTBJ
ADUKL
ADYCS
ADZOD
ADZYD
ADZZY
AECVZ
AEEZP
AENEX
AEQDE
AEQLS
AERKM
AEUHG
AEWDL
AEXFG
AEXNY
AFBPY
AFCOW
AFEBI
AFEET
AFKBI
AFKRG
AFRWT
AFUIA
AFVCE
AFWMB
AFZJQ
AGNHF
AGQPQ
AHEFC
AIGRN
AIWBW
AJABX
AJAOE
AJBDE
AJEFB
AJMMQ
AJSCY
AJUZI
AJXGE
ALMA_UNASSIGNED_HOLDINGS
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
B8M
B8O
B93
BDDNI
BFHJK
BKSCU
BSEHC
BYIEH
CAG
CBRKF
CDWPY
CFDXU
CO8
COF
CORYS
CQQTX
CS3
CUTAK
DC-
DC.
DC0
DC6
DCZOG
DD-
DD0
DE-
DOPDO
DU5
D~Y
EAD
EAP
EAS
EBC
EBD
EBS
EBX
ECV
EJD
EMB
EMK
EMOBN
ENC
EPT
ESX
F5P
FEDTE
FZ0
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HVGLF
HZI
HZ~
IHE
J8X
K.F
K.J
LH4
LW6
N9A
O9-
OIG
OVD
P.B
P2P
Q1R
Q7K
Q7R
Q7X
Q82
Q~Q
ROL
S01
SASJQ
SAUOL
SCDPB
SCNPE
SFC
SV3
TEORI
TUS
W99
WYUIH
YFH
ZGI
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
AAEJI
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c500t-92f7da37fc98848b4a4f5f6fdf81fb1fcf0ba2cb22e945acb1da9a53da5655a33
IEDL.DBID AFRWT
ISSN 0333-1024
1468-2982
IngestDate Thu Aug 21 14:11:39 EDT 2025
Fri Jul 11 11:24:41 EDT 2025
Mon Jul 21 06:05:43 EDT 2025
Tue Jul 01 05:25:42 EDT 2025
Thu Apr 24 23:05:04 EDT 2025
Tue Jun 17 22:45:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords transcranial magnetic stimulation
preventive treatment
single-pulse
Migraine
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c500t-92f7da37fc98848b4a4f5f6fdf81fb1fcf0ba2cb22e945acb1da9a53da5655a33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-3260-5904
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/0333102418762525?utm_source=summon&utm_medium=discovery-provider
PMID 29504483
PQID 2010843278
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5944078
proquest_miscellaneous_2010843278
pubmed_primary_29504483
crossref_citationtrail_10_1177_0333102418762525
crossref_primary_10_1177_0333102418762525
sage_journals_10_1177_0333102418762525
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-05-01
PublicationDateYYYYMMDD 2018-05-01
PublicationDate_xml – month: 05
  year: 2018
  text: 2018-05-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: Sage UK: London, England
PublicationTitle Cephalalgia
PublicationTitleAlternate Cephalalgia
PublicationYear 2018
Publisher SAGE Publications
Publisher_xml – name: SAGE Publications
References Hepp, Dodick, Varon 2015; 35
Andreou, Holland, Akerman 2016; 139
Brighina, Piazza, Vitello 2004; 227
Gaul, van Doorn, Webering 2011; 12
Gangitano, Valero-Cabre, Tormos 2002; 113
Bhola, Kinsella, Giffin 2015; 16
Holland, Akerman, Goadsby 2010; 30
Lipton, Dodick, Silberstein 2010; 9
Buse, Manack, Serrano 2010; 81
Romero, Anschel, Sparing 2002; 113
Brandes, Saper, Diamond 2004; 291
Lipton, Hamelsky, Dayno 2002; 42
2016; 388
Misra, Kalita, Bhoi 2013; 260
Lipton, Serrano, Holland 2013; 53
Teepker, Hotzel, Timmesfeld 2010; 30
Schoenen, Vandersmissen, Jeangette 2013; 80
Ramsey, Ryan, Hershey 2014; 54
Macedo, Banos, Farre 2008; 12
Fleiss 1993; 2
Lipton, Bigal, Diamond 2007; 68
Dodick, Loder, Manack Adams 2016; 56
Hepp, Dodick, Varon 2017; 37
Burstein, Jakubowski, Garcia-Nicas 2010; 68
Barker, Shields 2017; 57
Wassermann, Lisanby 2001; 112
Hochberg 1988; 75
Dodick, Schembri, Helmuth 2010; 50
Ayata, Jin, Kudo 2006; 59
Maeda, Keenan, Tormos 2000; 111
Rains, Penzien, Lipchik 2006; 46
Conforto, Amaro, Goncalves 2014; 34
Noseda, Kainz, Jakubowski 2010; 13
Silberstein, Neto, Schmitt 2004; 61
Goadsby, Charbit, Andreou 2009; 161
Afridi, Goadsby 2006; 10
Holland, Silberstein, Freitag 2012; 78
Kobayashi, Pascual-Leone 2003; 2
Peres, Silberstein, Moreira 2007; 47
Straube, Ellrich, Eren 2015; 16
bibr17-0333102418762525
bibr34-0333102418762525
bibr20-0333102418762525
bibr21-0333102418762525
bibr3-0333102418762525
bibr33-0333102418762525
bibr38-0333102418762525
bibr25-0333102418762525
bibr18-0333102418762525
bibr12-0333102418762525
bibr16-0333102418762525
bibr9-0333102418762525
bibr42-0333102418762525
bibr11-0333102418762525
bibr5-0333102418762525
bibr24-0333102418762525
bibr37-0333102418762525
bibr2-0333102418762525
bibr19-0333102418762525
bibr32-0333102418762525
Holland PR (bibr41-0333102418762525) 2010; 30
bibr28-0333102418762525
bibr15-0333102418762525
bibr6-0333102418762525
bibr23-0333102418762525
bibr10-0333102418762525
bibr31-0333102418762525
bibr1-0333102418762525
bibr36-0333102418762525
bibr14-0333102418762525
bibr40-0333102418762525
bibr27-0333102418762525
bibr7-0333102418762525
bibr29-0333102418762525
bibr30-0333102418762525
bibr22-0333102418762525
bibr35-0333102418762525
bibr26-0333102418762525
bibr39-0333102418762525
bibr4-0333102418762525
bibr8-0333102418762525
bibr13-0333102418762525
bibr43-0333102418762525
References_xml – volume: 227
  start-page: 67
  year: 2004
  end-page: 71
  article-title: rTMS of the prefrontal cortex in the treatment of chronic migraine: A pilot study
  publication-title: J Neurol Sci
– volume: 37
  start-page: 470
  year: 2017
  end-page: 485
  article-title: Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
  publication-title: Cephalalgia
– volume: 61
  start-page: 490
  year: 2004
  end-page: 495
  article-title: Topiramate in migraine prevention: Results of a large controlled trial
  publication-title: Arch Neurol
– volume: 56
  start-page: 821
  year: 2016
  end-page: 834
  article-title: Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
  publication-title: Headache
– volume: 260
  start-page: 2793
  year: 2013
  end-page: 2801
  article-title: High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: A randomized, placebo-controlled study
  publication-title: J Neurol
– volume: 161
  start-page: 327
  year: 2009
  end-page: 341
  article-title: Neurobiology of migraine
  publication-title: Neuroscience
– volume: 113
  start-page: 101
  year: 2002
  end-page: 107
  article-title: Subthreshold low frequency repetitive transcranial magnetic stimulation selectively decreases facilitation in the motor cortex
  publication-title: Clin Neurophysiol
– volume: 81
  start-page: 428
  year: 2010
  end-page: 432
  article-title: Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 68
  start-page: 81
  year: 2010
  end-page: 91
  article-title: Thalamic sensitization transforms localized pain into widespread allodynia
  publication-title: Ann Neurol
– volume: 388
  start-page: 1545
  year: 2016
  end-page: 1602
  article-title: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015
  publication-title: Lancet
– volume: 9
  start-page: 373
  year: 2010
  end-page: 380
  article-title: Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial
  publication-title: Lancet Neurol
– volume: 113
  start-page: 1249
  year: 2002
  end-page: 1257
  article-title: Modulation of input-output curves by low and high frequency repetitive transcranial magnetic stimulation of the motor cortex
  publication-title: Clin Neurophysiol
– volume: 13
  start-page: 239
  year: 2010
  end-page: 245
  article-title: A neural mechanism for exacerbation of headache by light
  publication-title: Nat Neurosci
– volume: 68
  start-page: 343
  year: 2007
  end-page: 349
  article-title: Migraine prevalence, disease burden, and the need for preventive therapy
  publication-title: Neurology
– volume: 16
  start-page: 543
  year: 2015
  article-title: Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A randomized, monocentric clinical trial
  publication-title: J Headache Pain
– volume: 2
  start-page: 145
  year: 2003
  end-page: 156
  article-title: Transcranial magnetic stimulation in neurology
  publication-title: Lancet Neurol
– volume: 42
  start-page: S3
  year: 2002
  end-page: S9
  article-title: What do patients with migraine want from acute migraine treatment?
  publication-title: Headache
– volume: 12
  start-page: 68
  year: 2008
  end-page: 75
  article-title: Placebo response in the prophylaxis of migraine: A meta-analysis
  publication-title: Eur J Pain
– volume: 46
  start-page: S142
  year: 2006
  end-page: S143
  article-title: Behavioral facilitation of medical treatment of headache: Implications of noncompliance and strategies for improving adherence
  publication-title: Headache
– volume: 50
  start-page: 1153
  year: 2010
  end-page: 1163
  article-title: Transcranial magnetic stimulation for migraine: A safety review
  publication-title: Headache
– volume: 30
  start-page: 519
  year: 2010
  end-page: 527
  article-title: Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors
  publication-title: Cephalalgia
– volume: 34
  start-page: 464
  year: 2014
  end-page: 472
  article-title: Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine
  publication-title: Cephalalgia
– volume: 30
  start-page: 137
  year: 2010
  end-page: 144
  article-title: Low-frequency rTMS of the vertex in the prophylactic treatment of migraine
  publication-title: Cephalalgia
– volume: 16
  start-page: 535
  year: 2015
  article-title: Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: Evaluation of outcome data for the UK post market pilot program
  publication-title: J Headache Pain
– volume: 12
  start-page: 475
  year: 2011
  end-page: 483
  article-title: Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: An observational study
  publication-title: J Headache Pain
– volume: 2
  start-page: 121
  year: 1993
  end-page: 145
  article-title: The statistical basis of meta-analysis
  publication-title: Stat Methods Med Res
– volume: 47
  start-page: 540
  year: 2007
  end-page: 545
  article-title: Patients' preference for migraine preventive therapy
  publication-title: Headache
– volume: 111
  start-page: 800
  year: 2000
  end-page: 805
  article-title: Modulation of corticospinal excitability by repetitive transcranial magnetic stimulation
  publication-title: Clin Neurophysiol
– volume: 291
  start-page: 965
  year: 2004
  end-page: 973
  article-title: Topiramate for migraine prevention: A randomized controlled trial
  publication-title: JAMA
– volume: 59
  start-page: 652
  year: 2006
  end-page: 661
  article-title: Suppression of cortical spreading depression in migraine prophylaxis
  publication-title: Ann Neurol
– volume: 35
  start-page: 478
  year: 2015
  end-page: 488
  article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine
  publication-title: Cephalalgia
– volume: 10
  start-page: 221
  year: 2006
  end-page: 224
  article-title: Neuroimaging of migraine
  publication-title: Curr Pain Headache Rep
– volume: 80
  start-page: 697
  year: 2013
  end-page: 704
  article-title: Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial
  publication-title: Neurology
– volume: 75
  start-page: 800
  year: 1988
  end-page: 802
  article-title: A sharper Bonferroni procedure for multiple testing of significance
  publication-title: Biometrika
– volume: 139
  start-page: 2002
  year: 2016
  end-page: 2014
  article-title: Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine
  publication-title: Brain
– volume: 54
  start-page: 795
  year: 2014
  end-page: 816
  article-title: Treatment adherence in patients with headache: A systematic review
  publication-title: Headache
– volume: 112
  start-page: 1367
  year: 2001
  end-page: 1377
  article-title: Therapeutic application of repetitive transcranial magnetic stimulation: A review
  publication-title: Clin Neurophysiol
– volume: 53
  start-page: 81
  year: 2013
  end-page: 92
  article-title: Barriers to the diagnosis and treatment of migraine: Effects of sex, income, and headache features
  publication-title: Headache
– volume: 78
  start-page: 1346
  year: 2012
  end-page: 1353
  article-title: Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
  publication-title: Neurology
– volume: 57
  start-page: 517
  year: 2017
  end-page: 524
  article-title: Transcranial magnetic stimulation: Basic principles and clinical applications in migraine
  publication-title: Headache
– ident: bibr24-0333102418762525
  doi: 10.1093/biomet/75.4.800
– ident: bibr23-0333102418762525
  doi: 10.1002/9780470316696
– ident: bibr35-0333102418762525
  doi: 10.1111/j.1526-4610.2010.01697.x
– ident: bibr7-0333102418762525
  doi: 10.1016/S1474-4422(03)00321-1
– ident: bibr11-0333102418762525
  doi: 10.1016/S1388-2457(01)00693-9
– ident: bibr42-0333102418762525
  doi: 10.1186/s10194-015-0543-3
– ident: bibr17-0333102418762525
  doi: 10.1002/ana.20778
– ident: bibr21-0333102418762525
  doi: 10.1212/WNL.0b013e3182825055
– ident: bibr32-0333102418762525
  doi: 10.1111/j.1526-4610.2007.00757.x
– ident: bibr30-0333102418762525
  doi: 10.1177/0333102416678382
– ident: bibr36-0333102418762525
  doi: 10.1136/jnnp.2009.192492
– ident: bibr33-0333102418762525
  doi: 10.1177/0333102414547138
– ident: bibr15-0333102418762525
  doi: 10.1016/j.jns.2004.08.008
– ident: bibr6-0333102418762525
  doi: 10.1016/S1474-4422(10)70054-5
– ident: bibr10-0333102418762525
  doi: 10.1016/S1388-2457(02)00109-8
– ident: bibr29-0333102418762525
  doi: 10.1111/head.12353
– ident: bibr14-0333102418762525
  doi: 10.1177/0333102413515340
– ident: bibr27-0333102418762525
  doi: 10.1212/WNL.0b013e3182535d0c
– ident: bibr8-0333102418762525
  doi: 10.1016/S1388-2457(99)00323-5
– ident: bibr28-0333102418762525
  doi: 10.1111/j.1526-4610.2006.00565.x
– volume: 30
  start-page: 519
  year: 2010
  ident: bibr41-0333102418762525
  publication-title: Cephalalgia
  doi: 10.1111/j.1468-2982.2009.02021.x
– ident: bibr9-0333102418762525
  doi: 10.1016/S1388-2457(01)00585-5
– ident: bibr37-0333102418762525
  doi: 10.1016/j.neuroscience.2009.03.019
– ident: bibr39-0333102418762525
  doi: 10.1038/nn.2475
– ident: bibr26-0333102418762525
  doi: 10.1111/head.12774
– ident: bibr3-0333102418762525
  doi: 10.1177/0333102416678382
– ident: bibr19-0333102418762525
  doi: 10.1001/archneur.61.4.490
– ident: bibr43-0333102418762525
  doi: 10.1016/j.ejpain.2007.03.002
– ident: bibr4-0333102418762525
  doi: 10.1111/head.13002
– ident: bibr16-0333102418762525
  doi: 10.1186/s10194-015-0535-3
– ident: bibr38-0333102418762525
  doi: 10.1007/s11916-006-0049-4
– ident: bibr2-0333102418762525
  doi: 10.1016/S0140-6736(16)31678-6
– ident: bibr18-0333102418762525
  doi: 10.1177/096228029300200202
– ident: bibr25-0333102418762525
  doi: 10.1111/j.1526-4610.2012.02265.x
– ident: bibr22-0333102418762525
  doi: 10.1177/0333102413485658
– ident: bibr34-0333102418762525
  doi: 10.1007/s10194-011-0348-y
– ident: bibr40-0333102418762525
  doi: 10.1002/ana.21994
– ident: bibr12-0333102418762525
  doi: 10.1007/s00415-013-7072-2
– ident: bibr13-0333102418762525
  doi: 10.1111/j.1468-2982.2009.01911.x
– ident: bibr20-0333102418762525
  doi: 10.1001/jama.291.8.965
– ident: bibr31-0333102418762525
  doi: 10.1046/j.1526-4610.2002.0420s1003.x
– ident: bibr1-0333102418762525
  doi: 10.1212/01.wnl.0000252808.97649.21
– ident: bibr5-0333102418762525
  doi: 10.1093/brain/aww118
SSID ssj0005606
Score 2.5266294
Snippet Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine....
Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine....
SourceID pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1038
SubjectTerms Adolescent
Adult
Aged
Female
Humans
Male
Middle Aged
Migraine Disorders - prevention & control
Original
Prospective Studies
Transcranial Magnetic Stimulation - methods
Treatment Outcome
Young Adult
Title A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
URI https://journals.sagepub.com/doi/full/10.1177/0333102418762525
https://www.ncbi.nlm.nih.gov/pubmed/29504483
https://www.proquest.com/docview/2010843278
https://pubmed.ncbi.nlm.nih.gov/PMC5944078
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ri9NAEB_OHohfxPfFx7GCiAeN3e5ms8nHnrYcQlVsi_ctbDa7etCm0gdy_70zefSsRfFbSDaTZWc28_rtDMArrRyqPe5DGTsekocQmsLGoSZ9zXWBJi05iuOP8cUs-nCpLo-gbM_CNCu4fkuwKpxR9bOm3U3R6F6TZOxxKdEsQeVDe1kJ9Og3i6yOdrdNNegOpae3C8psW8JDXoft6bZbcCx0rEQHjgejL1-nN6CQmNfZTUmILRHdJDYPvrmvyA6s00OQ5W9IsUp5je7B3cbqZINaTO7DkSsfwO1xk1d_CD8HrEIWEhW36jL8TnsEs8somjB3zKwWXUbNthgKjpvjdb6L6CLtqk4tW3q2no4nDE1htrj6Rv0nHFJzDaqSvRlOPn-aTYaM8IvXZ49gNhpO312ETUuG0CrON2EqvC6M1N6mSRIleWQir3zsC5_0fd731vPcCJsL4dJIGZv3C5MaJQuDhqMyUj6GTrks3Qkw6y03XmltnY-UQEoF2kYJujdCG5lHAfTa9c1sU6-c2mbMs35bovwPjgRwtnvjR12r4x9jX7Ysy3BDUZbElG65XWcED0giKXQSwJOahTtqIlUc_VkZgN5j7m4AFevef1Jefa-Kdqs0opRpAK9JDLJWzv86waf_O_AZ3MEpJzUI8zl0Nqute4GG0iY_Rek-f38-Om2k_BfBdg0v
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NnQS8THwTPo0EiEkNSx07Th54qKBVx9aBaCv2FhzHhklditpO0_4k_kvu8tFRKhAve4sU52L57nx3vp_vAF4oadHsBc4PIxv4FCH4OjeRr8heBypHl5YCxeFRNJiID8fyeAt-Nndh6hVcvCFYFc6o3KxX2k2VksIQPRK0O6TGkjd4ygN7cY7R2uLt_ntk7UvO-73xu4FfNxTwjQyCpZ9wp3IdKmeSOBZxJrRw0kUud3HHZR1nXJBpbjLObSKkNlkn14mWYa7R7ZGazj5xt98WEjf-Fmx3-5-_jC_xJFFQJUZDAntxcZkT3Zjzug3ccGw38Zm_gcxKu9e_CTu1w8q6lYTdgi1b3IZrwzolfwfOu6wEJRIVO28z_E9ze7PN6CBiapmen7YZ9eliKHN2is_Z6jAYaZclbtnMscV4OGLoRbPTk2_UusIiNVsDMtnr3ujTx8moxwj6eLF7FyZXsvj3oFXMCvsAmHEm0E4qZawTkiOlHN2qGCMjrnSYCQ_2mvVNTV3qnDpuTNNOU938D454sLv64kdV5uMfY583LEtRFynBogs7O1ukhCyIRchV7MH9ioUrajyRAYbCoQdqjbmrAVTne_1NcfK9rPctE0HZVg9ekRikjYr8dYIP_3fgM7g-GA8P08P9o4NHcAOnH1dYzsfQWs7P7BP0t5bZ01rSGXy9auX6BZqKNY8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NnTTxghifYQOMBIhJzeo6dpw87KFirTZGx0RbsbfgODab1KVT22naH8X_uHM-OkoF4mVvkeJcLN-d78738x3AOykMmj1q_SA01HcRgq8yHfrS2WsqM3RpXaDYPw4PRvzzqThdg1_1XZhqBWe7DlaFMyo2a6fdl5ltVTnGFg0C9ErQ9jhVFqzGVB6Zm2uM2GZ7h_vI3veM9brDTwd-1VTA14LSuR8zKzMVSKvjKOJRyhW3woY2s1Hbpm2rLU0V0yljJuZC6bSdqViJIFPo-gjlzj9xx1_nHGPKBqx3et--D-8wJSEtk6OBA3wxfpcXXZnzsh1ccW5XMZq_Ac0K29d7BA8rp5V0SinbhDWTP4aNfpWWfwLXHVIAEx0VM20S_E99g7NJ3GHE2BA1vWgS16uLoNyZMT6niwNhpF2UuSUTS2bD_oCgJ00uzn-69hUGqZkKlEk-dgcnX0eDLnHwx5udpzC6l8V_Bo18kpsXQLTVVFkhpTaWC4aUMnStIoyOmFRByj1o1eub6Krcueu6MU7adYXzPzjiwc7ii8uy1Mc_xr6tWZagProki8rN5GqWOHRBxAMmIw-elyxcUGOxoBgOBx7IJeYuBrha38tv8vOzoua3iLnLuHrwwYlBUqvJXyf48n8HvoGNk_1e8uXw-GgLHuDsoxLOuQ2N-fTKvEKXa56-rgSdwI_71q1bZK42qA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+multicenter%2C+prospective%2C+single+arm%2C+open+label%2C+observational+study+of+sTMS+for+migraine+prevention+%28ESPOUSE+Study%29&rft.jtitle=Cephalalgia&rft.au=Starling%2C+Amaal+J&rft.au=Tepper%2C+Stewart+J&rft.au=Marmura%2C+Michael+J&rft.au=Shamim%2C+Ejaz+A&rft.date=2018-05-01&rft.pub=SAGE+Publications&rft.issn=0333-1024&rft.eissn=1468-2982&rft.volume=38&rft.issue=6&rft.spage=1038&rft.epage=1048&rft_id=info:doi/10.1177%2F0333102418762525&rft_id=info%3Apmid%2F29504483&rft.externalDocID=PMC5944078
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0333-1024&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0333-1024&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0333-1024&client=summon